The purpose of this study is to determine the receptor occupancy (RO) associated with
telcagepant (MK-0974) administration based on displacement of [11C]MK-4232 from the CGRP
receptors in the brain using PET. The study enrolled healthy participants (Part I) and
migraine patients (Part III). Due to a protocol amendment, study Part II was not conducted.